David Sidransky - Rosetta Genomics Independent Director
Director
Dr. David Sidransky, M.D., is an Independent Director of the company since December 22, 2009. Dr. Sidransky is a renowned oncologist and research scientist named and profiled by TIME magazine in 2001 as one of the top physicians and scientists in America, recognized for his work with early detection of cancer. He serves as Executive Officer of Biomerk, Inc. and as Director of the Head and Neck Cancer Research Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University. He is a Professor of Oncology, Otolaryngology, Cellular Molecular Medicine, Urology, Genetics, and Pathology at John Hopkins University and Hospital. Dr. Sidransky has written over 400 peerreviewed publications, and has contributed to more than 50 cancer reviews and chapters. Dr. Sidransky is a founder of a number of biotechnology companies and holds numerous biotechnology patents. He was the recipient of many awards and honors, including the 1997 Sarstedt International prize from the German Society of Clinical Chemistry, 1998 Alton Ochsner Award Relating Smoking and Health by the American College of Chest Physicians and the 2004 Hinda Rosenthal Award presented by the American Association of Cancer Research. Dr. Sidransky has served as Vice Chairman of the Board of Directors, and presently is a director of ImClone. He serves on the board of directors of KV Pharmaceutical Co., Champions Biotechnology, Inc. and Morria Biopharmaceuticals Plc. and is Chairman of Tamir Biotechnology, Inc. . He is serving and has served on scientific advisory boards of corporations and institutions, including Amgen, MedImmune, Roche and Veridex, LLC, among others. In Addition, Dr. Sidransky served as Director of American Association for Cancer Research from 2005 to 2008 since 2009.
| Age | 56 |
| Tenure | 15 years |
| Phone | 972 73 222 0700 |
| Web | http://www.rosettagx.com |
David Sidransky Latest Insider Activity
Tracking and analyzing the buying and selling activities of David Sidransky against Rosetta Genomics stock is an integral part of due diligence when investing in Rosetta Genomics. David Sidransky insider activity provides valuable insight into whether Rosetta Genomics is net buyers or sellers over its current business cycle. Note, Rosetta Genomics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Rosetta Genomics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
David Sidransky over three weeks ago Acquisition by David Sidransky of tradable shares of Orgenesis at 5.42 subject to Rule 16b-3 | ||
David Sidransky over three months ago Acquisition by David Sidransky of 15495 shares of Champions Oncology subject to Rule 16b-3 | ||
David Sidransky over six months ago Acquisition by David Sidransky of 11480 shares of Champions Oncology subject to Rule 16b-3 |
Rosetta Genomics Management Efficiency
The company has return on total asset (ROA) of (60.19) % which means that it has lost $60.19 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (137.95) %, meaning that it created substantial loss on money invested by shareholders. Rosetta Genomics' management efficiency ratios could be used to measure how well Rosetta Genomics manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 2.45 M in liabilities with Debt to Equity (D/E) ratio of 222.8, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Rosetta Genomics has a current ratio of 2.05, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Rosetta Genomics until it has trouble settling it off, either with new capital or with free cash flow. So, Rosetta Genomics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Rosetta Genomics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Rosetta to invest in growth at high rates of return. When we think about Rosetta Genomics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Mark Thomas | Cimpress NV | 63 | |
| Ellen Artist | Mesa Air Group | 61 | |
| Daniel Altobello | Mesa Air Group | 76 | |
| John Steedman | WPP PLC ADR | N/A | |
| Zheng Du | Sunlands Technology Group | 40 | |
| Sam Sun | Sunlands Technology Group | 44 | |
| Yang Wang | Sunlands Technology Group | 45 | |
| Londa Dewey | WPP PLC ADR | 53 | |
| Tom Waldron | WPP PLC ADR | N/A | |
| Solomon | WPP PLC ADR | 65 | |
| Sandrine Dufour | WPP PLC ADR | 54 | |
| Solomon Trujillo | WPP PLC ADR | 67 | |
| Paul Richardson | WPP PLC ADR | 60 | |
| Gaoneng Ji | Sunlands Technology Group | 31 | |
| Sir Sorrell | WPP PLC ADR | 70 | |
| Keith Weed | WPP PLC ADR | 58 | |
| Chris Rollinson | WPP PLC ADR | N/A | |
| Graham Cubbin | WPP PLC ADR | N/A | |
| Nadia Shouraboura | Cimpress NV | 47 | |
| Gavin Molinelli | WPP PLC ADR | 30 | |
| Watts Humphrey | WPP PLC ADR | N/A | |
Management Performance
| Return On Equity | -137.95 | |||
| Return On Asset | -60.19 |
Rosetta Genomics Leadership Team
Elected by the shareholders, the Rosetta Genomics' board of directors comprises two types of representatives: Rosetta Genomics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Rosetta. The board's role is to monitor Rosetta Genomics' management team and ensure that shareholders' interests are well served. Rosetta Genomics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Rosetta Genomics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Sidransky, Independent Director | ||
| Kenneth Berlin, CEO and Pres | ||
| Anne Fields, IR Contact Officer | ||
| Joshua Rosensweig, Director | ||
| Dganit Bar, Chief Scientific Officer | ||
| Brian Markison, Chairman, Observer To Board of Directors and Member of Nominating and Corporate Governance Committee | ||
| Douglas Sites, Executive Vice President - Sales and Marketing | ||
| Tal YaronEldar, Independent Director | ||
| Eti Meiri, Vice President - Research | ||
| Robert Wassman, Chief Medical Officer | ||
| Oded Biran, General Counsel | ||
| Roy Davis, Director | ||
| Yitzhak Peterburg, Director | ||
| Kevin Watson, Director, Reimbursement-Managed Care | ||
| Ron Kalfus, CFO | ||
| Gerald Dogon, External Independent Director | ||
| Tali YaronEldar, External Independent Director |
Rosetta Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Rosetta Genomics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -137.95 | |||
| Return On Asset | -60.19 | |||
| Operating Margin | (370.55) % | |||
| Current Valuation | 2.09 M | |||
| Shares Outstanding | 5.93 M | |||
| Shares Owned By Insiders | 0.20 % | |||
| Shares Owned By Institutions | 14.42 % | |||
| Number Of Shares Shorted | 310.26 K | |||
| Price To Earning | (0.09) X | |||
| Price To Book | 1.01 X |
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Other Consideration for investing in Rosetta Stock
If you are still planning to invest in Rosetta Genomics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Rosetta Genomics' history and understand the potential risks before investing.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |